Page 54 - product-manual

TM/MC TM/MC
PHARMACOLOGICAL ACTIVITIES - TOXICOLOGY - DRUG INTERACTIONS

Passiflora incarnata (Passionflower)

Herba Passiflorae has been approved by The German Commission E for the treatment of
nervous unrest. In human studies Herba Passiflorae has been reported to reduce anxiety without
inducing sedation (Moavafegh et al., 2008). Based on pharmacological data, the experiences of
traditional use and the use in combinations, Herba Passiflorae extracts are an important factor
in the natural treatment of tenseness, restlessness and irritability with difficulty in falling asleep
(Krenn et al., 2002). In dogs, six months treatment with an extract containing Herba Passiflorae
and Radix Valerianae had no toxic effects (Tabach et al., 2009).

Toxicity for Herba Passiflorae has not been documented in dogs and cats when administered orally in therapeutic
doses. No side effects are known in humans when Herba Passiflorae is taken with recommended dosages
(Blumenthal, 2000). In toxicity studies, the LD of Herba Passiflorae was calculated to be: Extracts: oral: >15
TOXICOLOGY g/kg of body weight (mice and rats); intraperitoneal: 3,510 mg/kg of body weight (rats), 3,140 mg/kg of body
50
weight (mice); subcutaneous: >10 g/kg of body weight (rats), 8,300 mg/kg of body weight [mice] (EMEA, 2008).

Equivalent toxic dose in 20 kg dog: 300 g PO of Herba Passiflorae extract.
Equivalent toxic dose in 5 kg cat: 75 g PO of Herba Passiflorae extract.

DRUG Herba Passiflorae may potentiate the effects of pentobarbital (Speroni et al., 1996). Herba
INTERACTIONS Passiflorae may increase the sedative effects of benzodiazepines by increasing the binding
activity of benzodiazepines to GABA receptors (Carrasco et al., 2009).

Anzio-VM TM | 5